Skip to main content

Advertisement

Table 2 Univariate analyses of progression and minimal clinically important difference (MCID ≥ 5)

From: Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry

Variable Progression Minimal clinical important difference (MCID ≥5)
B 95% CI p OR 95% CI p
Strategy (monotherapy) 1.79 0.75–2.82 0.001 2.66 1.21–5.82 0.015
TJC28 −0.11 −0.20– -0.01 0.033 0.89 0.81–0.98 0.016
SJC28 0.01 −0.10–0.13 0.805 1.03 0.96–1.10 0.471
ESR 0.03 0.00–0.05 0.033 1.02 1.00–1.03 0.038
CRP 0.02 −0.00–0.04 0.084 1.01 1.00–1.02 0.071
Wellbeing −0.01 −0.04–0.01 0.196 0.99 0.98–1.01 0.319
PCS 0.01 −0.07–0.09 0.803 1.02 0.97–1.07 0.467
MCS −0.03 −0.09–0.04 0.408 1.01 0.97–1 .05 0.653
RF 0.09 −0.45–0.62 0.755 0.78 0.54–1.14 0.202
Anti-CCP positive 0.86 −0.23–1.95 0.123 2.41 1.04–5.57 0.040
Age 0.04 0.00–0.08 0.042 1.02 0.99–1.05 0.251
Gender 0.28 −0.82–1.38 0.621 0.75 0.36–1.56 0.443
DAS28_ESR −0.02 −0.51–0.47 0.948 0.94 0.67–1.31 0.708
Remission 52 weeks −0.83 −2.07–0.41 0.188 0.64 0.29–1.42 0.272
Remission 6 months −0.73 −1.79–0.34 0.179 0.54 0.26–1.11 0.094
Remission 3 months −0.90 −1.99–0.19 0.104 0.71 0.33–1.54 0.388
HAQ-SDI 0.62 −0.46–1.69 0.260 1.00 0.54–1.85 0.994
BMI −0.05 −0.17–0.07 0.417 0.91 0.83–1.00 0.039
Injection triamcinolone −1.63 −2.81– -0.46 0.007 0.39 0.15–1.07 0.067
  1. TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PCS physical component summary, MCS Mental component summary, DAS28 Disease Activity in 28 joints, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide, HAQ-SDI Health Assessment Questionnaire disability index (standard scoring), BMI body mass index